CAR T cell generation

IQ Irma Querques
AM Andreas Mades
CZ Cecilia Zuliani
CM Csaba Miskey
MA Miriam Alb
EG Esther Grueso
MM Markus Machwirth
TR Tobias Rausch
HE Hermann Einsele
ZI Zoltán Ivics
MH Michael Hudecek
OB Orsolya Barabas
request Request a Protocol
ask Ask a question
Favorite

Peripheral blood was obtained from healthy donors after written informed consent to participate in a research study. The study was approved by the Institutional Review Board of the University of Würzburg. Mononuclear cells were isolated by density centrifugation with Biocoll separating solution (Biochrom), and CD4+ and CD8+ T cells were sorted by negative isolation with immuno-magnetic associated cell sorting (MACS, Miltenyi). CD8+ and CD4+ primary human T cells were activated by anti-CD3/CD28 bead stimulation (Thermo Fisher). For assays in Fig. 4, two days after activation, CD19 CAR_EGFRt-encoding transposon MC and hsSB protein were transfected consecutively using a 4D-Nucleofector according to the manufacturer’s instructions (Lonza). 2 x 106 T cells were pulsed with 10 μg hsSB in a volume of 20 μl. LV transduction of controls was performed on day one by spinoculation. CAR T cells were propagated in RPMI-1640 with 10% (v/v) human serum, 2 mM L-glutamine, 100 U/ml penicillin-streptomycin and 50 U/ml IL-2. CAR-modified (i.e. EGFRt-positive) T cells were enriched using biotin-conjugated anti-EGFR mAb and anti-biotin beads (Miltenyi) and expanded with irradiated CD19+ feeder cells for 7 days. Functional analysis of CAR T cells was performed as described elsewhere6769. For assays in Fig. 6, two days after activation, 1 x 106 T cells were transfected with 0.5 μg CD19 CAR_EGFRt-encoding transposon MC in a volume of 20 μl using a 4D Nucleofector according to the manufacturer’s instructions (Lonza). Directly after electroporation, cells were incubated with 20 μg hsSB in a volume of 500 μl RPMI-1640 serum-free medium for 4 hours. Then, the medium was replaced with fresh serum-containing medium without hsSB. CD8+ T cells were cultured in RPMI-1640 with 10% (v/v) human serum, 2 mM L-glutamine, 100 U/ml penicillin-streptomycin and 50 U/ml IL-2 for additional five days. Then, CD3/CD28 beads were removed and CAR-modified (i.e. EGFRt-positive) T cells (~6.3% of the initial population, as determined by flow cytometry) were enriched using biotin-conjugated anti-EGFR mAb and anti-biotin beads (Miltenyi) and expanded using irradiated CD19+ feeder cells.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A